Template for submission of documentation for the single technology assessment of pharmaceuticals
Published:
|
Updated:
Changes
- : Updated guideline and template for submission.
- : Updated severity calculator
- : Health Technology Developers must now notify NOMA of planned STA submissions 2-3 months in advance instead of 2 weeks.
- : Revised template and new documentation for submission of STA
The submission guideline must be followed when submitting documentation for single technology assessment. To avoid delays in assessment, pharmaceutical companies are encouraged to use the template below when preparing documentation.
NOMA has revised the guideline and templates for submission as of July 6, 2026. Find more information about the latest revision.
The below templates are in accordance with the current guideline for submission of documentation for single technology assessment of medicinal products.
For medicinal products assessed under the European HTA Regulation, we incorporated clarifications in the template on parts of the documentation that are covered by European Joint Clinical Assessment (JCA).
NOMA invites health technology developers (HTDs) to an early dialogue to clarify the Norwegian PICO and to preliminary meetings for guidance on additional documentation required for a successful health technology assessment. Please contact the unit for HTA hospital medicines at NOMA.
These documents must be read together with the submission guideline:
In addition, these documents may be used to support the submission:
- Budget impact template (pre-filled example) (Excel)
- Tools for severity calculation and age adustment (Excel, effective September 1, 2025)
HTDs should notify NOMA by email of the planned submission date 2 to 3 months in advance. This will enable NOMA to plan and allocate resources accordingly.
Submission
Submit your documentation by e-mail to: post@noma.no, with a copy to either blaresept@noma.no (medicinal products funded by the National Insurance Scheme) or sykehus@noma.no (medicinal products funded by the Regional Health Authorities).
If the documentation exceeds the file size limits for e-mail, Eudralink and Cesp may be used.
It is important to include the following information in the e-mail: brand name of the product, active substance, and Nordic package number covered by the documentation.
File formatting and naming conventions are detailed in the submission checklist document (see above).
File names cannot exceed 42 characters due to technical requirements. Use abbreviations if necessary.